|
|
| Line 1: |
Line 1: |
| '''Quick Start:''' ''You can begin to add to or edit text on this wiki doc page by clicking on the edit button above and to the left on this same page. Type in the text you want to add. Once you are done, click the save changes button at the bottom.
| | #REDIRECT[[Fungal meningitis]] |
| | |
| ''''''
| |
| | |
| ==== Editor-In-Chief: ====
| |
| | |
| Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please email [[charlesmichaelgibson@gmail.com]] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| ----
| |
| | |
| = Overview =
| |
| | |
| ===== References =====
| |
| ----
| |
| = Epidemiology and Demographics =
| |
| :*100,000 infections/year
| |
| :*< 100 meningitis/year
| |
| :*95+% lethal at 2 years if untreated
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| | |
| = Risk Factors =
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| = Screening =
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| = Pathophysiology & Etiology=
| |
| :*Presents months after primary infection
| |
| :*CXR is often normal
| |
| ===== References =====
| |
| ----
| |
| | |
| = Molecular Biology =
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| = Genetics =
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| = Natural History =
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| = Diagnosis =
| |
| | |
| == Differential Diagnosis ==
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| == History and Symptoms ==
| |
| Most common Sx:
| |
| :*HA (n/v, blurry vision, change in MS)
| |
| | |
| ===== References =====
| |
| ----
| |
| | |
| == Physical Examination ==
| |
| | |
| === Appearance of the Patient ===
| |
| | |
| === Eyes ===
| |
| | |
| === Ear Nose and Throat ===
| |
| | |
| === Heart ===
| |
| | |
| === Lungs ===
| |
| | |
| === Abdomen ===
| |
| | |
| === Extremities ===
| |
| | |
| === Neurologic ===
| |
| | |
| === Other ===
| |
| | |
| ===== References =====
| |
| ----
| |
| == Laboratory Findings ==
| |
| | |
| === Electrolyte and Biomarker Studies ===
| |
| | |
| | |
| =====References=====
| |
| ----
| |
| | |
| === Electrocardiogram ===
| |
| | |
| | |
| =====References=====
| |
| ----
| |
| | |
| === Chest X Ray ===
| |
| | |
| | |
| =====References=====
| |
| ----
| |
| | |
| === MRI and CT ===
| |
| | |
| | |
| =====References=====
| |
| ----
| |
| | |
| === Echocardiography or Ultrasound ===
| |
| | |
| | |
| =====References=====
| |
| ----
| |
| | |
| === Other Imaging Findings ===
| |
| | |
| =====References=====
| |
| ----
| |
| === Other Diagnostic Studies ===
| |
| :*mild-moderate pleocytosis (PMN, Eos)
| |
| :*low glucose, high protein (250 mg/dL)
| |
| :*serology is most useful test
| |
| ===== References =====
| |
| ----
| |
| | |
| = Risk Stratification and Prognosis=
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| = Treatment =
| |
| | |
| | |
| == Pharmacotherapy ==
| |
| | |
| === Acute Pharmacotherapies ===
| |
| :*fluconazole
| |
| :*itraconazole
| |
| :*intrathecal ampho B
| |
| ===== References =====
| |
| ----
| |
| | |
| === Chronic Pharmacotherapies ===
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| | |
| == Surgery and Device Based Therapy ==
| |
| | |
| === Indications for Surgery ===
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| === Pre-Operative Assessment ===
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| | |
| === Post-Operative Management ===
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| === Transplantation ===
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| == Primary Prevention ==
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| == Secondary Prevention ==
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| == Cost-Effectiveness of Therapy ==
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| == Future or Investigational Therapies ==
| |
| | |
| | |
| ===== References =====
| |
| ----
| |
| | |
| ==Suggested Revisions to the Current Guidelines==
| |
| | |
| | |
| == References ==
| |
| <biblio>
| |
| </biblio>
| |
| ----
| |
| == Acknowledgements ==
| |
| The content on this page was first contributed by: Stephen Wiviott, M.D.
| |
| | |
| List of contributors:
| |
| ----
| |
| | |
| == Suggested Reading and Key General References ==
| |
| | |
| == Suggested Links and Web Resources ==
| |
| | |
| == For Patients ==
| |
| | |
|
| |
| | |
| ----
| |
| [[Category:]
| |
| {{WikiDoc Help Menu}}
| |